Guardant Health (GH) Rises +21.7% on Russell 1000 Inclusion and Analyst Upgrades
Key Takeaways
- Guardant Health (GH) shares surged approximately 21.7% over the last 30 days, climbing from $127.34 on June 16 to $155.00 by July 16, 2026.
- Inclusion in the Russell 1000 Index in late June triggered a wave of institutional buying and record trading volumes, with June 26 alone seeing over 18.7 million shares change hands.
- Multiple Wall Street firms raised price targets sharply — Canaccord Genuity to $205, Citigroup to $215, and Bernstein to $200 — reflecting growing confidence in the company's liquid biopsy pipeline.
- Over the last quarter, the stock has gained approximately 81%, driven by FDA regulatory wins, robust revenue growth, and expanding adoption of the Shield blood-based cancer screening platform.
- Despite the rally, notable insider selling and a consensus price target near $169 suggest investors should weigh upside momentum against valuation and execution risk.
Guardant Health (GH) Company Overview and Market Position
Guardant Health, Inc. is a precision oncology company headquartered in Palo Alto, California, that specializes in blood-based cancer diagnostics. Founded in 2012, the company develops non-invasive liquid biopsy tests that analyze circulating tumor DNA (ctDNA) to detect genomic alterations in patients with advanced solid tumors. Its flagship product, Guardant360 CDx, is a next-generation sequencing assay used by oncologists to guide targeted therapy decisions. The company's portfolio also includes Guardant Reveal for molecular residual disease testing and Shield, a blood-based test for colorectal cancer screening that received an FDA Breakthrough Device designation. Guardant Health serves clinical oncologists, pharmaceutical partners developing targeted therapies, and research institutions worldwide. With a market capitalization near $21 billion and institutional ownership exceeding 92%, GH is closely followed by investors betting on the shift toward less invasive, data-driven cancer diagnostics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Guardant Health (GH) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 calendar days, Guardant Health shares rose from a closing price of $127.34 on June 16, 2026, to $155.00 on July 16, 2026 — a gain of approximately +21.7%. The rally was not linear; the stock experienced sharp intraday swings and several sessions with above-average volume, most notably around the Russell index rebalancing period in late June. From what I see, the momentum built steadily before accelerating.
Zooming out to the quarterly picture, the performance is even more striking. Approximately three months ago, in mid-April 2026, GH traded near $85.70. The stock has since climbed roughly 81%, making it one of the strongest performers in the medical diagnostics sector. The 50-day moving average sits around $128, while the 200-day moving average is approximately $108, underscoring the sustained upward momentum that preceded and continued through the latest 30-day leg higher. I ran a quick check on similar names using Tickeron’s AI Trend Prediction Engine to put the move in context.
The Catalysts Behind GH Stock's 30-Day Move
The primary catalyst behind the 30-day surge was Guardant Health's addition to the Russell 1000 Index and several associated Russell growth and value benchmarks on June 27, 2026. Index rebalancing forced passive funds and institutional investors to add GH to their portfolios, driving record single-day volume of over 18.7 million shares on June 26 and propelling the stock from roughly $131 to above $149 within three sessions.
Simultaneously, a wave of bullish analyst actions amplified positive sentiment. Citigroup raised its price target to $215, Canaccord Genuity boosted its target to $205, and Bernstein lifted its target to $200 — all maintaining Buy or Outperform ratings. Goldman Sachs initiated coverage with a Buy rating and a $165 target. BTIG, Bank of America, and Guggenheim also raised their targets during this period. In July 2026, Guardant Health announced an exclusive partnership with Zydus Lifesciences and a memorandum of understanding with Apollo Hospitals to launch the Shield Multi-Cancer Detection blood test in India, opening a major international market. The company's Q1 2026 revenue of $302 million — up 48% year-over-year — continued to resonate with growth-oriented investors.
Drivers of the Broader Quarterly Rally in Guardant Health (GH)
The broader quarterly rally was fueled by a sequence of regulatory and clinical milestones. In May 2026, the U.S. Food and Drug Administration approved expanded labeling for Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, a targeted therapy for non-small cell lung cancer. This marked the largest liquid biopsy panel ever approved as a companion diagnostic and validated Guardant's platform as a critical tool in precision oncology.
Around the same time, the American Cancer Society recommended the Shield blood test for colorectal cancer screening, further validating the company's screening portfolio. These developments, combined with top-line revenue growth of 48% in Q1 and improving gross margins, created a powerful narrative around Guardant Health's transition from a diagnostic innovator to a commercially scaling enterprise. RBC Capital initiated coverage with an Outperform rating and a $185 target, while Mizuho raised its target to $175. The convergence of regulatory wins, clinical guideline inclusion, and analyst upgrades provided the foundational momentum that carried the stock through the quarter.
Exploring Tickeron’s Trending AI Robots
For investors seeking to navigate fast-moving stocks like Guardant Health, I often turn to Tickeron’s Trending AI Robots page. It offers a curated view of top-performing algorithmic trading strategies across thousands of tickers. Tickeron hosts hundreds of AI-powered trading bots, but only the most relevant and highest-performing ones are featured here. These bots employ diverse strategies — from swing trading to momentum-based and trend-following approaches — across multiple timeframes, each with transparent performance metrics. The section helps identify which algorithms are currently generating the strongest results, providing a useful data-driven complement to traditional analysis. In my view, it serves as a practical resource when evaluating momentum names like this one.
GH Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors will shape Guardant Health's trajectory. Payer coverage and adoption rates for the Shield blood-based colorectal cancer screening test in the U.S. remain the single most important commercial catalyst, as broad reimbursement could unlock a massive addressable market. The company's pending Q2 2026 earnings report will provide critical data on revenue momentum, test volumes, and progress toward narrowing operating losses — the company remains unprofitable, with a net loss of $112 million in Q1 2026.
International expansion efforts, including the India Shield launch with Zydus Lifesciences and Apollo Hospitals, represent a long-term growth lever but will take time to materially impact revenue. Competitive dynamics in the liquid biopsy space — where companies such as EXAS (Exact Sciences), NTRA (Natera), and ILMN (Illumina) also compete — merit close monitoring. Finally, investors should track analyst sentiment, as the consensus price target of approximately $169 implies limited near-term upside from current levels, while the most bullish targets above $200 suggest conviction in the long-term growth story remains divided.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GH sees MACD Histogram just turned negative
GH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 41 instances where the indicator turned negative. In of the 41 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for GH moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GH as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GH broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 191 cases where GH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GH's P/B Ratio (60.976) is slightly higher than the industry average of (13.092). P/E Ratio (0.000) is within average values for comparable stocks, (151.393). GH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.636). GH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (18.349) is also within normal values, averaging (7.717).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of diagnostic technologies to improve cancer management
Industry MedicalSpecialties
Advertisement